Skip to main content

Featured

Canadians Are Feeling Less Squeezed — But Fraud Is Rewriting How We Manage Credit

  New data from TransUnion's Q2 2026 Canada Consumer Pulse Study, released July 22, 2026 There's a small but real shift happening in Canadian households right now. After years of headlines about affordability and inflation, a new survey suggests things are slightly less bleak — but Canadians aren't relaxing. They're getting more careful, and increasingly, more worried about fraud than about their credit score. TransUnion's newest Consumer Pulse Study, out today, paints a picture of a country cautiously exhaling — while quietly tightening the locks on its financial front door. The Good News: A Little More Breathing Room For the first time in a while, the numbers aren't all doom. Roughly a quarter of Canadians surveyed said their household income rose over the past three months, and nearly one in four say their finances are running better than they expected this year — the best reading TransUnion has recorded in the past 12 months. Optimism is edging up too: 45% ...
Post a Comment
Read more

article

Labels

A New Dawn in Alzheimer’s Prevention: The AHEAD 3-45 Study


The AHEAD 3-45 study represents a beacon of hope for individuals like Tyson Haller, who, at 60, is determined to understand and possibly prevent the onset of Alzheimer’s—a disease that claimed his father. This groundbreaking clinical trial is testing lecanemab, an FDA-approved drug that has shown promise in slowing Alzheimer’s progression in its early stages. The optimism surrounding this trial is palpable, as it could herald a new era where Alzheimer’s is as manageable as Type 2 diabetes.

  • Family History’s Weight: Haller’s participation is driven by his family’s battle with Alzheimer’s, highlighting the emotional and proactive steps taken by those at risk.
  • Lecanemab’s Potential: The trial’s focus on lecanemab, a drug targeting beta amyloid plaques in the brain, offers a glimpse into a future where early intervention could significantly slow the disease’s impact.
  • Scientific Debate: Despite the excitement, there’s a scientific debate about beta amyloid’s role in Alzheimer’s, underscoring the complexity of finding a definitive treatment.
  • Awaiting Results: With the AHEAD and TRAILBLAZER prevention trials running until 2027 and 2029, patients, doctors, and researchers are in a state of limbo, hopeful yet uncertain of the long-term outcomes.

This study not only represents a potential turning point in Alzheimer’s research but also embodies the personal stories of those fighting to preserve their memories and identities against this relentless disease.

Labels:

Comments

Post a Comment